\
&
Contact us
Published on | 1 hour ago
ProgrammesEIT Jumpstarter is designed for early-stage teams that want to turn an idea into a business. It is a seven-month pre-acceleration programme for early-stage innovators from more than 28 countries and territories. Teams can apply in seven thematic categories and compete for a first prize of up to €10,000, with several additional special prizes of €2,500. The programme also includes coaching, in-person training, travel support and links with innovation hubs across Europe.
Applicants (at least 1 participating team member) must hold citizenship from one of the following countries or regions:
Applicants can submit ideas in seven categories: Food & Agritech, Healthcare, Energy & Renewables, Smart Cities & Urban Mobility, Advanced and Green Manufacturing, Metals, Minerals and Industrial Side Streams, and a Malta-focused strand supporting startups and innovations.
Interested applicants can review the eligibility rules, thematic scope and application guidance on the programme website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.